Insulin-like growth factor 1 opposes the effects of C-reactive protein on endothelial cell activation

Molecular and Cellular Biochemistry

Volumn 385, Issue 1-2, 2014, Pages 199-205

  Liu, Shao Jun ^a   Zhong, Yun ^a   You, Xiang Yu ^a   Liu, Wei Hua ^a   Li, Ai Qun ^a   Liu, Shi Ming ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; CRP; Endothelial activation; IGF 1; PI3K Akt

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; C REACTIVE PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN C JUN; PROTEIN KINASE B; SOMATOMEDIN C; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CELL FUNCTION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; PATHOPHYSIOLOGY; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

C-REACTIVE PROTEIN; CORONARY VESSELS; CYTOPROTECTION; ENDOTHELIAL CELLS; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; JNK MITOGEN-ACTIVATED PROTEIN KINASES; NITRIC OXIDE SYNTHASE TYPE III; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-JUN; SIGNAL TRANSDUCTION;

EID: 84890474115     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1828-y     Document Type: Article

References (37)

1. Ferri C, Croce G, Cofini V, De Berardinis G, Grassi D, Casale R, Properzi G, Desideri G (2007) C-reactive protein: interaction with the vascular endothelium and possible role in human atherosclerosis. Curr Pharm Des 13:1631-1645
2. Koenig W (2005) Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein. Int J Cardiol 98:199-206
3. Paffen E, DeMaat MP (2006) C-reactive protein in atherosclerosis: a causal factor? Cardiovasc Res 71:30-39
4. Zhong Y, Li SH, Liu SM, Szmitko PE, He XQ, Fedak PW, Verma S (2006) C-Reactive protein upregulates receptor for advanced glycation end products expression in human endothelial cells. Hypertension 48:504-511
5. Conti E, Carrozza C, Capoluongo E, Volpe M, Crea F, Zuppi C, Andreotti F (2004) Insulin-like growth factor-1 as a vascular protective factor. Circulation 110:2260-2265
6. Conti E, Musumeci MB, De Giusti M, Dito E, Mastromarino V, Autore C, Volpe M (2011) IGF-1 and atherothrombosis: relevance to pathophysiology and therapy. Clin Sci (Lond) 120:377-402
7. Kaplan RC, Strickler HD, Rohan TE, Muzumdar R, Brown DL (2005) Insulin-like growth factors and coronary heart disease. Cardiol Rev 13:35-39
8. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T (2002) Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 106:939-944
9. Tvarijonaviciute A, Eralp O, Kocaturk M, Yilmaz Z, Ceron JJ (2010) Adiponectin and IGF-1 are negative acute phase proteins in a dog model of acute endotoxaemia. Vet Immunol Immunopathol 140:147-151
10. Pardina E, Ferrer R, Baena-Fustegueras JA, Lecube A, Fort JM, Vargas V, Catalan R, Peinado-Onsurbe J (2010) The relationships between IGF-1 and CRP, NO, leptin, and adiponectin during weight loss in the morbidly obese. Obes Surg 20:623-632
11. Colangelo LA, Chiu B, Kopp P, Liu K, Gapstur SM (2009) Serum IGF-I and C-reactive protein in healthy black and white young men: the CARDIA male hormone study. Growth Horm IGF Res 19:420-425
12. Lawlor DA, Ebrahim S, Smith GD, Cherry L, Watt P, Sattar N (2008) The association of insulin-like-growth factor 1 (IGF-1) with incident coronary heart disease in women: findings from the prospective British women's heart and health study. Atherosclerosis 201:198-204
13. Efstratiadis G, Tsiaousis G, Athyros VG, Karagianni D, Pavlitou-Tsiontsi A, Giannakou-Darda A, Manes C (2006) Total serum insulin-like growth factor-1 and C-reactive protein in metabolic syndrome with or without diabetes. Angiology 57:303-311
14. Lee SD, Huang CY, Shu WT, Chen TH, Lin JA, Hsu HH, Lin CS, Liu CJ, Kuo WW, Chen LM (2006) Pro-inflammatory states and IGF-I level in ischemic heart disease with low or high serum iron. Clin Chim Acta 370:50-56
15. Wallander M, Brismar K, Ohrvik J, Ryden L, Norhammar A (2006) Insulin-like growth factor I: a predictor of long-term glucose abnormalities in patients with acute myocardial infarction. Diabetologia 49:2247-2255
16. Deepak D, Daousi C, Javadpour M, Clark D, Perry Y, Pinkney J, Macfarlane IA (2010) The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency. Growth Horm IGF Res 20:220-225
17. Franco C, Andersson B, Lonn L, Bengtsson BA, Svensson J, Johannsson G (2007) Growth hormone reduces inflammation in postmenopausal women with abdominal obesity: a 12-month, randomized, placebo-controlled trial. J Clin Endocrinol Metab 92:2644-2647
18. McCallum RW, Sainsbury CA, Spiers A, Dominiczak AF, Petrie JR, Sattar N, Connell JM (2005) Growth hormone replacement reduces C-reactive protein and large-artery stiffness but does not alter endothelial function in patients with adult growth hormone deficiency. Clin Endocrinol (Oxf) 62:473-479
19. Ma S, Liu S, Huang Q, Xie B, Lai B, Wang C, Song B, Li M (2012) Site-specific phosphorylation protects glycogen synthase kinase-3beta from calpain-mediated truncation of its N and C termini. J Biol Chem 287:22521-22532
20. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I (2002) Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106:1439-1441
21. Pasceri V, Willerson JT, Yeh ET (2000) Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102:2165-2168
22. Qamirani E, Ren Y, Kuo L, Hein TW (2005) C-reactive protein inhibits endothelium-dependent NO-mediated dilation in coronary arterioles by activating p38 kinase and NAD(P)H oxidase. Arterioscler Thromb Vasc Biol 25:995-1001
23. Xu JW, Morita I, Ikeda K, Miki T, Yamori Y (2007) C-reactive protein suppresses insulin signaling in endothelial cells: role of spleen tyrosine kinase. Mol Endocrinol 21:564-573
24. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Saito T, Manabe I, Imai Y, Nagai R (2006) C-reactive protein induces VCAM-1 gene expression through NF-kappaB activation in vascular endothelial cells. Atherosclerosis 185:39-46
25. Liang YJ, Shyu KG, Wang BW, Lai LP (2006) C-reactive protein activates the nuclear factor-kappaB pathway and induces vascular cell adhesion molecule-1 expression through CD32 in human umbilical vein endothelial cells and aortic endothelial cells. J Mol Cell Cardiol 40:412-420
26. Anand SS, Yusuf S (2010) C-reactive protein is a bystander of cardiovascular disease. Eur Heart J 31:2092-2096
27. Bisoendial RJ, Boekholdt SM, Vergeer M, Stroes ES, Kastelein JJ (2010) C-reactive protein is a mediator of cardiovascular disease. Eur Heart J 31:2087-2091
28. Schunkert H, Samani NJ (2008) Elevated C-reactive protein in atherosclerosis-chicken or egg? N Engl J Med 359:1953-1955
29. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG (2008) Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359:1897-1908
30. Turu MM, Slevin M, Matou S, West D, Rodriguez C, Luque A, Grau-Olivares M, Badimon L, Martinez-Gonzalez J, Krupinski J (2008) C-reactive protein exerts angiogenic effects on vascular endothelial cells and modulates associated signalling pathways and gene expression. BMC Cell Biol 9:47
31. Chen Y, Wang J, Yao Y, Yuan W, Kong M, Lin Y, Geng D, Nie R (2009) CRP regulates the expression and activity of tissue factor as well as tissue factor pathway inhibitor via NF-kappaB and ERK 1/2 MAPK pathway. FEBS Lett 583:2811-2818
32. Wallez Y, Huber P (2008) Endothelial adherens and tight junctions in vascular homeostasis, inflammation and angiogenesis. Biochim Biophys Acta 1778:794-809
33. Escudero-Esparza A, Jiang WG, Martin TA (2012) Claudin-5 participates in the regulation of endothelial cell motility. Mol Cell Biochem 362:71-85
34. Tai LM, Holloway KA, Male DK, Loughlin AJ, Romero IA (2010) Amyloid-beta-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J Cell Mol Med 14:1101-1112
35. Ramirez SH, Fan S, Dykstra H, Rom S, Mercer A, Reichenbach NL, Gofman L, Persidsky Y (2013) Inhibition of glycogen synthase kinase 3β promotes tight junction stability in brain endothelial cells by half-life extension of occludin and claudin-5. PLoS ONE 8:e55972
36. Vandenbroucke E, Mehta D, Minshall R, Malik AB (2008) Regulation of endothelial junctional permeability. Ann N Y Acad Sci 1123:134-145
37. Higashi Y, Sukhanov S, Anwar A, Shai SY, Delafontaine P (2010) IGF-1, oxidative stress and atheroprotection. Trends Endocrinol Metab 21:245-254